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Background: Sexual dysfunction is common in patients with end stage renal disease (ESRD) and treatment options
are limited. Observational studies suggest that nocturnal hemodialysis may improve sexual function. We compared
sexual activity and responses to sexual related questions in the Kidney Disease Quality of Life Short Form
questionnaire among patients randomized to frequent nocturnal or thrice weekly conventional hemodialysis.
Methods: We performed a secondary analysis of data from an RCT which enrolled 51 patients comparing frequent
nocturnal and conventional thrice weekly hemodialysis. Sexual activity and responses to sexual related questions
were assessed at baseline and six months using relevant questions from the Kidney Disease Quality of Life Short
Form questionnaire.
Results: Overall, there was no difference in sexual activity, or the extent to which people were bothered by the
impact of kidney disease on their sex life between the two groups between randomization and 6 months. However,
women and patients age< 60 who were randomized to frequent nocturnal hemodialysis were less bothered by the
impact of kidney disease on their sex life at 6 months, compared with patients allocated to conventional
hemodialysis (p = 0.005 and p = 0.024 respectively).
Conclusions: Our results suggest that frequent nocturnal hemodialysis is not associated with an improvement in
sexual activity in all patients but might have an effect on the burden of kidney disease on sex life in women and
patients less than 60 years of age. The validity of these subgroup findings require confirmation in future RCTs.
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Sexual dysfunction is common in men and women with
end stage renal disease (ESRD) [1–5], contributed to by
both the diseases that cause ESRD, as well as the conse-
quences of kidney failure [4,6]. Recently, Vecchio et al.
published a systematic review examining the treatments
available to ESRD patients with sexual dysfunction [7].
Their report highlights the limited treatment options avail-
able, noting that phosphodiesterase-5 inhibitors improve
erectile dysfunction in men with ESRD, with little research
available to guide therapy in women with ESRD.
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reproduction in any medium, provided the orand among other reported benefits, some studies have
reported improved sexual function. Published literature
however shows conflicting results, although these are
based mainly on small observational studies comparing
pre-NHD to post-NHD quality of life scores, usually com-
pared with patients on conventional hemodialysis (CvHD)
[8–12]. Ting et al. followed 42 patients and noted that sex-
ual function improved after conversion to NHD [11] while
Lockridge et al. observed an increase in sexual desire after
NHD initiation in 40 patients [10]. However, other studies
have not documented improvement, including a recent
prospective observational study of 63 patients which
demonstrated no improvement in sexual function scores
after conversion to NHD [9].
Our group has previously reported a randomized con-
trolled trial in which we examined the effects of NHD
on both left ventricular mass as well as quality of life
[13–15]. One of the quality of life tools used was the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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questionnaire [16], containing specific questions asses-
sing sexual arousal and sexual enjoyment. These ques-
tions have not been analyzed nor reported previously.
Herein we report the results of a post hoc analysis to de-
termine if frequent NHD was associated with an im-
provement in sexual activity and responses to sexual
related questions listed in the Kidney Disease Quality of




The methods of this study have previously been reported
in detail [15]. Patients were recruited from 10 hemodialysis
centers in Alberta, Canada. Patients were considered eli-
gible if they were 18 years old and they were receiving in-
center, self-care or home CvHD 3 times a week. In
addition to being interested in NHD, patients had to be
willing to train and start NHD. Exclusion criteria included
physical or mental impediment to training for NHD. Eth-
ics approval was obtained from the Conjoint Health Re-
search Ethics Board at the University of Calgary and
informed consent was obtained from all participants.
Fifty-one patients were randomized to either frequent
NHD or CvHD in a two group parallel design. Patients
randomized to frequent NHD were trained to perform
NHD at home for 5-6 nights per week at a minimum of
6 hours, while those randomized to CvHD continued
thrice weekly conventional hemodialysis [14]. For the
majority of patients treated with CvHD, dialysis was
delivered in-centre. Quality of life questionnaires were
administered prior to randomization, at the baseline
study visit (corresponding to the first day of NHD train-
ing for the NHD group), and at study end at 6 months.
Outcome measures
There are many relevant measures of sexual function,
which are outlined below in Table 1. This table also
includes a list of the measures that we were able to assess
and compares them to contemporary measure of sexual
function. The primary outcome that we used was whether
patients were sexually active or not, which is easily assess-
able, though does not capture all relevant domains of
sexual function. The secondary outcomes (sexual function,
enjoyment and burden of kidney disease on sex life) were
measured with questions included within the KDQOL-SF
[16]. The questions have been previously validated [17] as
a reasonable proxy of sexual function. The relevant ques-
tions from the KDQOL-SF were as follows:
Sexual activity and enjoyment questions:
1. Have you had any sexual activity in the past 4
weeks? (yes / no)2. If yes, then how much of a problem was each of the
following in the past 4 weeks?
A.) Enjoying sex?
B.) Becoming sexually aroused?
Burden of kidney disease on sex life question
(answered by all participants):
3. Some people are bothered by the effects of kidney
disease on their daily life, while others are not. How
much does kidney disease bother you . . . with
respect to. . .Your sex life?
The responses to the two sexual enjoyment and
arousal questions and the burden of kidney disease on
sex life question were recorded on a five point Likert
scale, ranging from 1 to 5 (1 representing no problem or
not bothered and 5 indicating a severe problem or ex-
tremely bothered). For the secondary outcomes, we
chose to examine the proportion of patients who
reported improvement. The burden of kidney disease on
sex life question was answered and analysed in all
patients, while the sexual enjoyment and arousal ques-
tions were answered and analysed only in patients who
had sexual activity in the prior 4 weeks.
Statistical analysis
To confirm the reliability of the sexual arousal and en-
joyment question, Cronbach’s alpha was calculated on
these questions in patients who declared that they had
engaged in sexual activity. In addition, to verify the
validity of analyzing the burden of kidney disease on
sex life question alone, Pearson’s R correlation coeffi-
cient was determined between this question and the
sexual enjoyment and arousal question in those parti-
cipants who had engaged in sexual activity. A Cron-
bach’s alpha was also calculated between the three
questions together to determine if taken together, they
demonstrate reliability in measuring sexually related
concerns.
All analyses used the intention to treat principle and
all enrolled patients were included in the analysis. For
the primary outcome (sexual activity), we first assessed
whether there was a higher proportion of patients
reporting sexual activity using Chi square tests. We next
compared changes in burden of kidney disease scores
from randomization to study end (6 months) between
patients allocated to frequent NHD and conventional
hemodialysis. Since there is no requirement in the
KDOQL-SF for a patient to be engaged in sexual activity
to answer the burden of kidney disease on sex life ques-
tion, and since we were interested in whether NHD
reduced the burden of kidney disease on sex life – an
outcome that is relevant, irrespective of sexual activity,
Table 1 Description of Contemporary Measures of Quality of Sexual Function in comparison to the KDQOL-SF
Inventory Name Modality/gender Number of items Domains
Kidney Disease Quality of Life Short
Form (KDQOL-SF) ***Present Study
SR/male and female 4 Sexual activity, satisfaction,




SR/male and female 5 Drive, arousal, penile erection/vaginal lubrication,
orgasm, satisfaction
































SR/female only 26 Desire, arousal–sensation,
arousal–lubrication,
enjoyment, orgasm, dyspareunia,
partner relationship, overall total score
Sexual interest and
desire inventory
CI 13 Overall total score
Short scale to measure
female sexual
functioning (SPEQ)






SR/female only 12/13 Unidimensional scale measuring
sexually related personal distress.
'R' version has an
additional desire item
Abbreviations: CI = clinical interview; SR = self report (Adapted with permission from Derogatis [26]).
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activity. Given that we were testing differences in pro-
portions, we used chi-square tests and applied the
Yates continuity correction for analyses that did not
meet the 5 items expected per cell criteria. For missing
data at six months (n = 3; due to death or loss to
transplantation), we used the last value carried forward
approach [14].
Among the subgroup of patients reporting sexual
activity, we next categorized patients based on whether
they experienced an improvement for both the domains
“enjoying sex”, or “becoming sexually aroused”. This was
chosen because it is considered a clinically significant
change [13]. Statistical significance was defined as a
p-value< 0.05.
Since the causes and prevalence of sexual dysfunction
differs across patients with ESRD, we performedexploratory analyses to determine if there was any subpo-
pulation of patients who might benefit from nocturnal
hemodialysis with respect to sexual function. All sub-
groups were conceived prior to analyzing the data. These
included women, patients <60 years of age, patients with-
out vascular disease, and patients without diabetes. It was
not possible to analyze any subgroups for the sexual activ-
ity question due to the small numbers of patients who
were sexually active. However, we chose to do subgroup
analysis on the burden of kidney disease question since
there was no requirement to be sexually active to answer
the question. All statistical analyses were performed using
STATA software package version 11.
Results
The baseline characteristics between the two groups are
listed in Table 2. Fifty-one patients answered the QOL





Age (years) 55.1 ± 12.4 53.1 ± 13.4
Male gender (%) 18 (69) 14 (56)
Caucasian (%) 23 (88) 21 (84)
Time on dialysis (years) 5.5 ± 5.3 4.8 ± 3.8
Median (interquartile range) 3 (1–9) 4 (2–6)
Baseline dialysis modality (%)
In-center hemodialysis 18 (69) 13 (52)
Home or self-care hemodialysis 2 (8) 5 (20)
Home hemodialysis 6 (23) 7 (28)
Cause of ESRD (%)
Diabetic nephropathy 7 (27) 8 (32)
Hypertension/vascular 2 (8) 2 (8)
Glomerulonephritis 5 (19) 8 (32)
Polycystic kidney disease 3 (12) 1 (4)
Urologic 3 (12) 3 (12)
Other 6 (24) 3 (12)
Comorbid illnesses (%)
Ischemic heart disease 10 (38) 10 (40)
Congestive heart failure 6 (23) 5 (20)
Peripheral vascular disease 4 (15) 4 (16)
Cerebrovascular disease 5 (19) 3 (12)
Diabetes mellitus 10 (38) 11 (44)
β-Blocker usage (%) 10 (38) 9 (36)
Married, Common-law or in 18 (72) 19 (73)
Relationship (%)
Responses to relevant sexual questions Baseline 6 Months Baseline 6 Months
Proportion with Sexual Activity in Last 4 Weeks 36% 32% 38% 31%
Proportion of patients very much or
extremely bothered on burden of
Kidney Disease on Sex Life
60% 39% 50% 40%
Proportion of patients having sex who
reported very much or severe
problems enjoying Sex*
55% 70% 40% 88%
Proportion of patients having sex who
reported very much or severe problem
becoming Sexually Aroused*
55% 70% 40% 88%
ESRD, end-stage renal disease.
Values (±) are means ± standard deviation.
P> 0.05 for all comparisons between nocturnal hemodialysis and conventional.
*proportion of patients engaging in sexual activity.
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significant differences in baseline characteristics were
detected between the two groups. Approximately 1/3 of
patients had diabetes and the cohort was relatively young
with an average age of 55 in the NHD group and 53 in
the CvHD group. The majority of patients who partici-
pated in the study were Caucasian and a greaterproportion of participants were male than female. There
was no difference in the number of patients in relation-
ships in either group with 72% with a partner in the
NHD group and 73% in the CvHD group.
The Cronbach’s alpha of the sexual arousal and enjoy-
ment questions was 0.97 in patients who had engaged in
sexual activity indicating excellent reliability of these
Figure 1 Percentage of patients reporting sexual activity by dialysis modality at randomization and at six months.
Bass et al. BMC Nephrology 2012, 13:67 Page 5 of 7
http://www.biomedcentral.com/1471-2369/13/67questions. The Pearson R correlation coefficient of the
burden of kidney disease on sex life question was 0.61
(p = 0.01) with both the sexual enjoyment and arousal
questions indicating a strong correlation between these
questions. The Cronbach’s alpha of all three questions
analyzed together was 0.89 suggesting good reliability.
With respect to our primary outcome, there was no
change in the proportion of patients who reported being
sexually active at six months compared to randomization
(Figure 1). Of the patients with recent sexual activity,
there was also no significant difference between the two
groups at 6 months when changes in the proportion ofFigure 2 Proportion of patients showing improvement in burden of k
of patients in each group according to modality. All categories not statistic
(**p = 0.02).patients enjoying sex or becoming sexually aroused were
considered.
For the burden of kidney disease on sex life question
(a measure of sexual function), at six months, 39%
patients in the NHD group had scores indicating that
they were not at all bothered to moderately bothered by
sexual dysfunction, compared with 60% in the CvHD
group (p= 0.28). When comparing the burden of kidney
disease scores, 45% and 32% of NHD and conventional
hemodialysis patients, respectively, experienced an im-
provement by one category in their scores (p= 0.2)
(Figure 2). In women and patients below the age ofidney disease on sex life. Listed above the columns are the number
ally significantly different except Women (*p = 0.02) and Age< 60
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ment in burden of kidney disease on sex life scores for
patients allocated to nocturnal hemodialysis (χ2 = 7.90,
p= 0.02 and χ2 = 5.12 p= 0.02) (Figure. 2).
Discussion
In this post-hoc analysis of a randomized controlled trial
we observed no improvement in sexual activity or or
self-reported arousal, enjoyment or burden of kidney dis-
ease on sex life between patients on NHD versus CvHD
overall. Consistent with prior reports of sexual activity
on hemodialysis, only 43 percent of patients indicated
that they were sexually active in the 4 weeks prior to ei-
ther randomization or study completion [3]. Our find-
ings are not consistent with prior research suggesting
that NHD may improve sexual activity and sexually
related concerns.
Normal sexual function involves a complex interplay
between the hormonal, vascular, neurological and psy-
chological systems. These can all be impacted by ESRD.
Patients with ESRD have abnormalities in the
hypothalamic-pituitary axis, in particular, hypogonadism
and hyperprolactinemia which are thought to be second-
ary to the accumulation of uremic toxins [18]. The dis-
eases that cause ESRD and the condition itself can cause
vascular insufficiency as well as sensory and autonomic
neuropathy [4]. Finally, the complex social and psycho-
logical factors that are embroiled with ESRD impact nor-
mal sexual function [19]. Given this, the mechanism by
which NHD might improve sexual function in ESRD
patients is not clear. Since NHD improves clearance of
uremic toxins it might improve hormonal dysfunction,
but it may not address other inhibitors of normal sexual
function. NHD does not alleviate the comorbid condi-
tions that cause ESRD which are well known to cause
sexual dysfunction. Specifically, NHD is unlikely to re-
verse pre-existing vascular and neurological damage
causing impairment. In addition, it may have variable
effects on the social and psychological dynamics caused
by ESRD. In particular, sexual activity might be either
positively or negatively affected by undergoing dialysis in
the home. Transplantation provides a good example of
the potential multi-factorial nature of sexual dysfunction
in that despite normalization of kidney function, many
patients still experience sexual dysfunction [20].
While we did not note any improvement with NHD on
sexual activity or self-reported arousal, enjoyment or
burden of kidney disease on sex life overall, a subgroup
analysis suggested that patients less than 60 years of age
and women were less burdened by the effect of their kid-
ney disease on their sex life after 6 months of NHD. It is
plausible that younger patients might be more likely to
experience benefit with NHD since it is conceivable that
they might have fewer and less severe comorbid diseases,which themselves may impair sexual function. It is un-
certain why women might benefit from NHD with re-
spect to the burden of kidney disease of sex life. While
both sexes suffer from decreased libido, there are differ-
ences in sexual dysfunction between men and women
with ESRD with men generally suffering from impotence
[4] and women suffering from anorgasmia, decreased lu-
brication and dyspareunia [21]. NHD may have no im-
pact on impotence in men, while it is possible that
women perceive NHD to be less intrusive on normal
sexual function than CvHD. While this study did not
specifically measure these outcomes, it is possible that
changes in these domains could have impacted the bur-
den of kidney disease on sex-life in these sub-groups. Al-
ternatively, while the burden kidney disease on sex life
diminished in these patients, there are other burdens
aside from kidney disease that may be impacting proper
sexual activity and function which may explain why we
did not observe a concomitant increase in sexual activity.
Our study is the first randomized controlled trial docu-
menting the association between NHD and sexual activ-
ity and self-reported sexual function. However, it has
several limitations which should be considered. The ori-
ginal RCT was not specifically designed to examine the
impact of NHD on sexual function. While the KDQOL-
SF does include domains designed to measure sexual
function and activity, it would have been preferable to
use dedicated sexual function scales such as the Inter-
national Index of Erectile Function [22] or the Female
Sexual Function Index [23]. Despite this, we feel that our
study provides much needed insight into a poorly stud-
ied area that is pervasive in dialysis patients. Other lim-
itations include that the RCT was not powered to detect
differences in quality of life, and that all analyses docu-
mented herein are posthoc and exploratory in nature.
Given the limited number of patients and that few
patients answered the sexual function questions, our
subgroup findings should be interpreted with particular
caution. However, our findings can be tested within sec-
ondary analyses of other recently reported randomized
trials of frequent hemodialysis [24,25]. It should also be
noted that given the nature of the intervention it is
highly unlikely that a randomized controlled trial fo-
cussed on this particular outcome will ever be
undertaken.Conclusions
In conclusion, our study is the first randomized con-
trolled trial examining the effect of NHD on sexual ac-
tivity or self-reported sexual arousal, enjoyment or
burden of kidney disease on sex life. While NHD does
not appear to improve sexual activity overall, women
and patients younger than 60 years old might experience
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should be assessed in future RCTs.
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